2,906 Shares in Vertex Pharmaceuticals Incorporated $VRTX Bought by Bluebird Wealth Management LLC

Bluebird Wealth Management LLC acquired a new stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 2,906 shares of the pharmaceutical company’s stock, valued at approximately $1,317,000.

Other hedge funds have also bought and sold shares of the company. Mitsubishi UFJ Asset Management Co. Ltd. increased its position in Vertex Pharmaceuticals by 3.8% during the third quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 544,978 shares of the pharmaceutical company’s stock valued at $213,435,000 after acquiring an additional 20,053 shares during the last quarter. Danske Bank A S bought a new position in Vertex Pharmaceuticals during the third quarter valued at $64,417,000. Leuthold Group LLC bought a new position in shares of Vertex Pharmaceuticals in the third quarter worth about $5,030,000. Legacy Capital Group California Inc. bought a new position in shares of Vertex Pharmaceuticals in the third quarter worth about $956,000. Finally, ING Groep NV bought a new position in shares of Vertex Pharmaceuticals in the third quarter worth about $4,695,000. Institutional investors own 90.96% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Barclays raised their target price on shares of Vertex Pharmaceuticals from $607.00 to $615.00 and gave the stock an “overweight” rating in a research report on Wednesday. Cantor Fitzgerald reiterated an “overweight” rating and issued a $590.00 price target on shares of Vertex Pharmaceuticals in a report on Friday, February 13th. Scotiabank boosted their price target on Vertex Pharmaceuticals from $495.00 to $558.00 and gave the company an “outperform” rating in a report on Friday, February 13th. UBS Group boosted their price target on Vertex Pharmaceuticals from $535.00 to $545.00 and gave the company a “buy” rating in a report on Monday, January 26th. Finally, Bank of America boosted their price target on Vertex Pharmaceuticals from $571.00 to $598.00 and gave the company a “buy” rating in a report on Tuesday, March 10th. One analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $555.17.

Key Headlines Impacting Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Germany reimbursement for CASGEVY secures payer access for eligible patients (age ≥12) with sickle cell disease and transfusion‑dependent beta thalassemia — a meaningful commercial milestone for a one‑time gene‑editing therapy. Business Wire: CASGEVY reimbursement
• Positive Sentiment: Q1 results: adjusted EPS beat estimates ($4.47 vs. $4.24) and revenue grew ~8% to $2.99B, driven by CF franchise and recently launched products — supports medium‑term revenue trajectory. Zacks: Q1 earnings beat
• Positive Sentiment: Industry recognition: National Kidney Foundation honored Vertex with a 2026 Kidney Biotech Innovation Award — incremental reputational/PR support for non‑CF pipeline work. Yahoo Finance: NKF award
• Neutral Sentiment: Company reiterated 2026 guidance (revenue roughly in line with consensus) — provides stability but limits upside surprise potential. Investor slide deck (Q1)
• Neutral Sentiment: Analysts reacted by trimming price targets while generally remaining constructive — many keep Buy/Outperform ratings but lowered near‑term upside. Benzinga: Analyst revisions after Q1
• Negative Sentiment: Insider selling reported (EVP Joy Liu sold ~1,104 shares; Director Sangeeta Bhatia sold 318 shares) under 10b5‑1 plans — routine but can pressure sentiment when clustered after earnings. InsiderTrades: insider selling
• Negative Sentiment: Market reaction was muted to negative after the quarter: some commentators say the update was “mixed” (beat on EPS but other reads left investors cautious), prompting near‑term profit‑taking. Yahoo: Is it too late to consider VRTX?
• Negative Sentiment: Debate over growth strategy: some analysts/commentators argue Vertex may need bolder M&A to diversify beyond CF and accelerate non‑CF pipeline commercialization — strategic risk that could temper valuation expansion. Seeking Alpha: Q1 review / M&A commentary
• Negative Sentiment: Small insider option grant reported (Michel Lagarde acquired ~$9K in options) — modest signal but immaterial to near‑term share moves. Benzinga: Michel Lagarde options

Insider Activity at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP Duncan Mckechnie sold 4,910 shares of the stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $487.65, for a total transaction of $2,394,361.50. Following the completion of the sale, the executive vice president directly owned 17,559 shares of the company’s stock, valued at approximately $8,562,646.35. This represents a 21.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Mark E. Bunnage sold 2,021 shares of the stock in a transaction dated Wednesday, February 11th. The shares were sold at an average price of $460.43, for a total transaction of $930,529.03. Following the sale, the executive vice president directly owned 12,914 shares of the company’s stock, valued at approximately $5,945,993.02. The trade was a 13.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 81,853 shares of company stock worth $38,479,135 over the last quarter. Corporate insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Price Performance

Shares of Vertex Pharmaceuticals stock opened at $427.65 on Thursday. Vertex Pharmaceuticals Incorporated has a 1 year low of $362.50 and a 1 year high of $507.92. The firm’s 50-day moving average is $451.70 and its two-hundred day moving average is $449.73. The stock has a market cap of $108.78 billion, a price-to-earnings ratio of 25.36, a PEG ratio of 1.85 and a beta of 0.30.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Monday, May 4th. The pharmaceutical company reported $4.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.24 by $0.23. Vertex Pharmaceuticals had a net margin of 35.51% and a return on equity of 23.86%. The company had revenue of $2.99 billion for the quarter, compared to analysts’ expectations of $2.99 billion. During the same period in the prior year, the business earned $4.06 EPS. The firm’s quarterly revenue was up 8.3% on a year-over-year basis. On average, equities analysts expect that Vertex Pharmaceuticals Incorporated will post 16.81 earnings per share for the current year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.